DALLAS, July 22, 2019 /PRNewswire/ -- New Parks Associates research finds 13% of heads of US broadband households ages 65 and older consider the ability to interact with an independent living system using voice controls as a must-have feature. By comparison, 30% of current caregivers consider voice control a must-have feature. The research firm will address the

MISGAV, Israel, July 22, 2019 /PRNewswire/ -- The Trendlines Group Ltd. ("Trendlines") (SGX: 42T) (OTCQX: TRNLY) today announced that it has signed a Subscription Agreement with Librae Holdings Limited ("LH"), for an SGD10.88 million (USD8 million) investment. London-based discret

DUBLIN, July 22, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in an oral presentation at the 32nd European Neurology Congress. New data demonstrat

SAN DIEGO, July 22, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinicall

SUNNYVALE, Calif., July 22, 2019 /PRNewswire/ -- EBR Systems, Inc., developer of the world's only wireless cardiac pacing system for heart failure, today announced that the College of the French National Authority for Health (Haute Autorite de Sante, HAS) awarded a Forfait Innovation Package for the company's WiSE™ Cardiac Resynchronization Therapy (CRT) Syste

SAN MATEO, Calif., July 22, 2019 /PRNewswire/ -- Apixio Inc., the AI healthcare analytics company, today announced it has promoted Tom McNamara to the role of Chief

TORONTO, July 22, 2019 /PRNewswire/ - LifeSpeak Inc, a digital total wellbeing platform that helps keep employees present, productive and thriving, is proud to announce it has agreed to preferred contracting terms with Lockton.  LifeSpeak will work with Lockton, the world's largest privately owned, independent insurance brokerage, and select clients to provide

CUPERTINO, Calif., July 22, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT's SABER® technology.  Gilead also received exclusive a

NEW YORK, July 22, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced initial results of

BOSTON, July 22, 2019 /PRNewswire/ -- For children battling illnesses, the "dog days of summer" just got a little brighter thanks to the Dunkin' Joy in Childhood Foundation's